V
60
2
SPG
55
5
CTSH
44
2
BLK
61
3
ILMN
36
-5
LRCX
59
6
EXR
55
5
HAS
53
2
FLR
50
-9
WYNN
46
5
SEE
57
2
PHM
74
3
OKE
59
3
QCOM
82
2
FOXA
38
3
GOOG
91
2
NRG
80
3
TDC
70
2
ALLE
39
-9
NTRS
35
5
V
60
2
SPG
55
5
CTSH
44
2
BLK
61
3
ILMN
36
-5
LRCX
59
6
EXR
55
5
HAS
53
2
FLR
50
-9
WYNN
46
5
SEE
57
2
PHM
74
3
OKE
59
3
QCOM
82
2
FOXA
38
3
GOOG
91
2
NRG
80
3
TDC
70
2
ALLE
39
-9
NTRS
35
5
Financhill
Back

Travere Therapeutics 10K Form

Sell
29

TVTX
Travere Therapeutics

Last Price:
6.2600
Seasonality Move:
-0.72%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive TVTX News And Ratings

See the #1 stock for the next 7 days that we like better than TVTX

TVTX Financial Statistics

Sales & Book Value

Annual Sales: $145.24M
Cash Flow: $-76M
Price / Cash Flow: 0
Annual Sales: $2.66
Price / Book: 2.37

Profitability

EPS (TTM): -1.61000
Net Income (TTM): $-111.4M
Gross Margin: $133.79M
Return on Equity: -67.19%
Return on Assets: -14.51%

Travere Therapeutics Earnings Forecast

Key Travere Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 11 years for TVTX is 92.12%.
  • The Selling, General & Administrative Expenses for TVTX have been equal to 182.83% of Gross Profit Margin.
  • The Research & Development expenses have been 168.68% of Revenue.
  • The Interest Expense is -10.17% of Operating Income.
  • The Net Earning history of TVTX is -76.70% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 4 years.

Travere Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: TVTX
CUSIP: 89422G
Website: travere.com

Debt

Debt-to-Equity Ratio: 1.88
Current Ratio: 3.47
Quick Ratio: 3.31

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

TVTX Technical Analysis vs Fundamental Analysis

Sell
29
Travere Therapeutics (TVTX) is a Sell

Is Travere Therapeutics a Buy or a Sell?